FAP and neoplasm: A 177Lu-labeled bivalent FAPI (ND-bisFAP) demonstrated eight-fold higher binding affinity to FAP-expressing cells, higher specific tumor uptake, and retention in vivo, four-fold higher radiation delivery, greater reduction in tumor growth but comparable median survival in study animals than 177Lu-labeled cells expressing monomeric complexing agent dodecane tetraacetic acid (DOTA)-FAPI-04 [560].